Exelixis Inc (EXEL) 5.88 $EXEL
Critical Alerts For Lumber Liquidators, Exelixis, Ford, Intuitive Surgical and Rite Aid Released By InvestorsObserver
PR Newswire - Thu Jul 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LL, EXEL, F, ISRG and RAD.
ISRG: 557.20 (+7.32), F: 14.61 (+0.19), LL: 19.69 (+0.08), RAD: 8.79 (-0.04), EXEL: 5.88 (-0.43)
The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 8:30AM CDT
The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie
AMGN: 164.10 (-0.15), ABBV: 70.52 (-0.04), REGN: 556.61 (+0.08), FPRX: 24.47 (-0.58), EXEL: 5.88 (-0.43)
Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
M2 - Wed Jul 22, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4277fl/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. Based on drugs, the global glioblastoma treatment market has been segmented into Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU). The market for these drugs has been extensively analyzed based on consistency, effectiveness, and sales revenue of the drugs developed by the manufacturers. The market size and forecast in terms of USD million for each drug has been provided for the period from 2012 to 2022. Based on pipeline review, the global glioblastoma treatment market has been segmented into late stage (phase III) and early stage (Phase I&II). Drugs available in phase I and II are shown in a tabular format (significance, indication and intervention etc.). Likewise, the market size and forecast in terms of USD million for phase III candidate has been forecasted from 2014 to 2022. A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the glioblastoma treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include AbbVie, Inc., Activartis Biotech GmbH, Bristol-Myers Squibb Co., Merrimack Pharmaceuticals, Inc., F. Hoffman La Roche, and Tau Therapeutics. The pipeline review of glioblastoma treatment market has been segmented as below: Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs - Bevacizumab (Avastin) - Temozolomide (Temodar and Temodal and Temcad) - Carmustine (BiCNU) Global Pipeline Review of Glioblastoma Treatment - Overview - Late Stage (Phase III) - - DCVax - - Rindopepimut (CDX-110) - - Others - Early Stage (Phase I, II and Pre clinical) - - ABT-414 - - MM-398 - - ARC-100 - - AV0113 - - Cotara - - Crenolanib - - SGT-53 - - Endostatin - - ANG1005 - Others Companies Mentioned - AbbVie, Inc. - Activartis GmbH - Agenus Inc. - Arog Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.) - Cavion LLC - Celldex Therapeutics Inc. - Cortice Biosciences Inc. - Eisai Co., Ltd. - Exelixis Inc. - F. Hoffmann-La Roche Ltd. - Merrimack Pharmaceuticals, Inc. - OncoSynergy - Peregrine Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/42...ioblastoma
MACK: 10.43 (unch), CLDX: 25.33 (-0.21), ABBV: 70.52 (-0.04), CTIC: 1.92 (+0.01), BMY: 68.24 (-1.13), EXEL: 5.88 (-0.43)
Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 22, 9:52AM CDT
Amgen's (AMGN) potential blockbuster, Repatha, is the first PCSK9 inhibitor to gain approval in the world for the treatment of high cholesterol.
BIIB: 385.05 (-6.69), ALXN: 207.84 (+1.68), AMGN: 164.10 (-0.15), ABBV: 70.52 (-0.04), REGN: 556.61 (+0.08), FPRX: 24.47 (-0.58), EXEL: 5.88 (-0.43)
Exelixis (EXEL) Stock Declines on Secondary Public Offering
at The Street - Wed Jul 22, 8:54AM CDT
Exelixis (EXEL) shares are falling after the company announced the public offering of 20 million shares, just days after the stock spiked 50% on positive trial data.
EXEL: 5.88 (-0.43)
Biotechnology Sector Stocks Technical Coverage -- Amgen, Exelixis, XOMA Corp., Theravance, and NewLink Genetics
PR Newswire - Wed Jul 22, 8:22AM CDT
Equity Research Institute has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Theravance Inc. (NASDAQ: THRX), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research report on Amgen can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AMGN On Tuesday, July 21, 2015, the NASDAQ Composite ended at 5,208.12, down 0.21%, the Dow Jones Industrial Average declined 1.00%, to finish the day at 17,919.29, and the S&P 500 closed at 2,119.21, down 0.43%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
NLNK: 53.32 (-1.69), AMGN: 164.10 (-0.15), THRX: 15.62 (-0.25), XOMA: 1.04 (+0.04), EXEL: 5.88 (-0.43)
Exelixis proposes public offering of 20m common stock
M2 - Wed Jul 22, 4:33AM CDT
Biopharmaceutical company Exelixis (Nasdaq:EXEL) said on Tuesday that it intends to issue 20,000,000 shares of its common stock in an underwritten public offering.
EXEL: 5.88 (-0.43)
Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 5:40PM CDT
Exelixis' (EXEL) Cometriq scores in a late-stage study (METEOR) in patients with metastatic renal cell carcinoma.
EBIO: 2.91 (+0.01), AMAG: 71.31 (-1.23), NVS: 103.05 (+1.75), EXEL: 5.88 (-0.43)
Chesapeake Energy and IBM are big market movers
AP - Tue Jul 21, 3:24PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
HAS: 79.28 (-0.57), HOG: 58.25 (-0.36), CNX: 17.84 (+0.45), LMT: 202.83 (+0.04), EBAY: 28.43 (-0.02), LII: 117.39 (-0.11), CF: 62.32 (-0.20), CHK: 8.71 (-0.34), HAL: 42.33 (+0.79), CZR: 5.14 (+0.38), VZ: 46.35 (-0.10), EXEL: 5.88 (-0.43)
Exelixis Launches Proposed Public Offering of Common Stock
Business Wire - Tue Jul 21, 3:01PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today announced that it plans to offer, subject to market and other conditions, 20,000,000 shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock in connection with the offering. All of the shares of common stock in the offering will be sold by Exelixis.
EXEL: 5.88 (-0.43)
Ewing Sarcoma Pipeline Report 2015 - 15 Companies & 23 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z9h72l/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - Amgen Inc. - Cebiotex, S.L. - EntreChem, S.L. - Exelixis, Inc. - Gradalis Inc. - Kolltan Pharmaceuticals, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Oncomatrix, S.L. - Recombio S.L - Shionogi & Co., Ltd. - Sigma-Tau S.p.A. - Tesaro, Inc. Drug Profiles - 3BP-227 - cabozantinib s-malate - cancer vaccine - CEB-01 - celyvir - dactinomycin next generation - Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - EC-8042 - EC-8105 - everolimus - ganitumab - irinotecan sucrosofate liposomal - KIT-SG3227 - Monoclonal Antibody Conjugated for Ewing Sarcoma - Monoclonal Antibody to Inhibit GD2 for Oncology - MTX2-NIG - niraparib - pazopanib hydrochloride - pembrolizumab - racotumomab - S-588410 - SP-2509 - SST-0001 For more information visit http://www.researchandmarkets.com/research/z9...ng_sarcoma
MACK: 10.43 (unch), TSRO: 62.20 (-1.76), MRK: 58.07 (-0.06), AMGN: 164.10 (-0.15), NVS: 103.05 (+1.75), EXEL: 5.88 (-0.43)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 25.33 (-0.21), NBS: 2.25 (-0.09), CLSN: 2.50 (+0.09), JNJ: 100.20 (+0.02), ABBV: 70.52 (-0.04), EXEL: 5.88 (-0.43), ONCY: 0.61 (-0.03), CERU: 4.24 (+0.04), PFE: 34.78 (-0.10), IMGN: 18.15 (-0.77), AMGN: 164.10 (-0.15), LLY: 86.76 (+0.38), CLVS: 85.96 (-0.06), AZN: 66.55 (-0.67), MRK: 58.07 (-0.06), NVS: 103.05 (+1.75)
Progression Survival Benefit - BrokerBank Securities
PR Newswire - Tue Jul 21, 8:00AM CDT
Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company that develops and markets treatments for cancer. The company is in its development stage with one approved treatment. The two most advanced assets of the company are Cabozantinib, and Cobimetinib. Exelixis has five Phase III trials for various cancer treatments using Cabozantinib and Cobimetinib. On top of those, the company has numerous strategic partnerships with other drug companies, and multiple treatments in Phase II trials. Exelixis has a huge pipeline of potential uses for its treatments.
EXEL: 5.88 (-0.43)
Potential Kidney Cancer Drugs Could Revolutionize Treatment
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 21, 7:05AM CDT
Source: Bristol-Myers Squibb. If treated early enough, kidney cancer patients have a five-year survival rate that is better than many other cancers. Unfortunately, though, treatment options are more limited, and survival rates less optimistic, for...
BMY: 68.24 (-1.13), EXEL: 5.88 (-0.43)
Soft Tissue Sarcoma Therapeutics Pipeline Report 2015 - Review of 46 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vws7wm/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Altor BioScience Corporation - Amgen Inc. - Bayer AG - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - CASI Pharmaceuticals Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - Gem Pharmaceuticals, LLC - Immune Design Corp. - Karyopharm Therapeutics, Inc. - Loxo Oncology, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - MolMed S.p.A. - Morphotek, Inc. - Nanobiotix - Neotropix, Inc. - Novartis AG - Oncos Therapeutics Ltd. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/vw...oft_tissue
LOXO: 17.51 (-0.14), CLRB: 3.31 (-0.08), IMDZ: 25.82 (-1.17), PFE: 34.78 (-0.10), AMGN: 164.10 (-0.15), LLY: 86.76 (+0.38), EPZM: 22.15 (+0.05), CASI: 1.64 (-0.07), MACK: 10.43 (unch), BLCM: 18.79 (-0.32), MRK: 58.07 (-0.06), CYTR: 2.80 (-0.03), MRTX: 29.91 (-1.27), NVS: 103.05 (+1.75), KPTI: 22.95 (-0.26), EXEL: 5.88 (-0.43), CELGZ: 2.20 (-0.09)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Pipeline Review 2015 - Analysis of 35 Companies & 43 Drug Profiles
M2 - Tue Jul 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dp6kl/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca PLC - Bayer AG - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Komipharm International Co., Ltd. - Mebiopharm Co., Ltd. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - NuCana BioMed Limited - OncoTherapy Science, Inc. - Panacea Pharmaceuticals, Inc. - PCI Biotech AS - Pfizer Inc. - Provecs Medical GmbH - Sanofi - Senhwa Biosciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - AG-120 - ARN-5032 - ARQ-087 - BBI-503 - BGJ-398 - binimetinib - cabozantinib s-malate - CAP-7.1 - CC-90007 - CPI-613 - dasatinib - DKN-01 - elpamotide - evofosfamide - gemcitabine hydrochloride - Im-01 - KML-001 - MBPY-005 - melphalan - merestinib - MK-2206 - NUC-1031 - OCVC-01 - paclitaxel albumin bound - PAN-622 - pembrolizumab - ponatinib hydrochloride - porfimer sodium For more information visit http://www.researchandmarkets.com/research/6d...uct_cancer
PFE: 34.78 (-0.10), ARQL: 1.81 (-0.01), SPPI: 7.13 (-0.17), LLY: 86.76 (+0.38), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), MACK: 10.43 (unch), MRK: 58.07 (-0.06), AZN: 66.55 (-0.67), AGIO: 118.42 (+1.04), DCTH: 0.49 (-0.01), NVS: 103.05 (+1.75), ARRY: 6.59 (-0.06), CELGZ: 2.20 (-0.09), CXRX: 78.92 (+0.27), EXEL: 5.88 (-0.43)
Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 148.05 (+4.05), ARQL: 1.81 (-0.01), GALE: 1.67 (-0.03), EXEL: 5.88 (-0.43), XLRN: 31.50 (-0.68), INCY: 113.21 (-1.21), IMGN: 18.15 (-0.77), GSK: 42.00 (-0.30), ONTY: 3.60 (-0.03), AZN: 66.55 (-0.67), MRK: 58.07 (-0.06), AVEO: 1.61 (+0.01), PBYI: 98.75 (-1.25), KPTI: 22.95 (-0.26), NVS: 103.05 (+1.75)
Bristol-Myers: kidney drug win
at Investor's Business Daily - Mon Jul 20, 5:41PM CDT
The big pharma said that its Opdivo scored another win Mon. as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. The trial compared Opdivo with everolimus, better known as Novartis' (NVS) Afinitor, in...
BMY: 68.24 (-1.13), EXEL: 5.88 (-0.43), NVS: 103.05 (+1.75)
Market Wrap: A Tech-Led Tick Higher
at The Street - Mon Jul 20, 3:45PM CDT
But energy and materials names, crude oil and gold all dropped.
HOG: 58.25 (-0.36), IBM: 161.73 (+1.38), UTX: 101.14 (-0.41), SUNE: 26.30 (-1.40), KKR: 24.27 (+0.18), VSLR: 15.79 (-0.05), VZ: 46.35 (-0.10), BHI: 59.26 (+0.98), EXEL: 5.88 (-0.43)
Exelixis' Meteroric Rise From the Ashes
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 20, 1:33PM CDT
Score one for tenacity. Exelixis is up almost 50% today after releasing positive results from its phase 3 trial, dubbed Meteor, testing its drug Cometriq in patients with kidney cancer. It's been a long road to get here. Like many...
EXEL: 5.88 (-0.43)
Critical Alerts For Lumber Liquidators, Exelixis, Ford, Intuitive Surgical and Rite Aid Released By InvestorsObserver
PR Newswire - Thu Jul 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LL, EXEL, F, ISRG and RAD.
ISRG: 557.20 (+7.32), F: 14.61 (+0.19), LL: 19.69 (+0.08), RAD: 8.79 (-0.04), EXEL: 5.88 (-0.43)
The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 8:30AM CDT
The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie
AMGN: 164.10 (-0.15), ABBV: 70.52 (-0.04), REGN: 556.61 (+0.08), FPRX: 24.47 (-0.58), EXEL: 5.88 (-0.43)
Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
M2 - Wed Jul 22, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4277fl/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. Based on drugs, the global glioblastoma treatment market has been segmented into Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU). The market for these drugs has been extensively analyzed based on consistency, effectiveness, and sales revenue of the drugs developed by the manufacturers. The market size and forecast in terms of USD million for each drug has been provided for the period from 2012 to 2022. Based on pipeline review, the global glioblastoma treatment market has been segmented into late stage (phase III) and early stage (Phase I&II). Drugs available in phase I and II are shown in a tabular format (significance, indication and intervention etc.). Likewise, the market size and forecast in terms of USD million for phase III candidate has been forecasted from 2014 to 2022. A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the glioblastoma treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include AbbVie, Inc., Activartis Biotech GmbH, Bristol-Myers Squibb Co., Merrimack Pharmaceuticals, Inc., F. Hoffman La Roche, and Tau Therapeutics. The pipeline review of glioblastoma treatment market has been segmented as below: Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs - Bevacizumab (Avastin) - Temozolomide (Temodar and Temodal and Temcad) - Carmustine (BiCNU) Global Pipeline Review of Glioblastoma Treatment - Overview - Late Stage (Phase III) - - DCVax - - Rindopepimut (CDX-110) - - Others - Early Stage (Phase I, II and Pre clinical) - - ABT-414 - - MM-398 - - ARC-100 - - AV0113 - - Cotara - - Crenolanib - - SGT-53 - - Endostatin - - ANG1005 - Others Companies Mentioned - AbbVie, Inc. - Activartis GmbH - Agenus Inc. - Arog Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.) - Cavion LLC - Celldex Therapeutics Inc. - Cortice Biosciences Inc. - Eisai Co., Ltd. - Exelixis Inc. - F. Hoffmann-La Roche Ltd. - Merrimack Pharmaceuticals, Inc. - OncoSynergy - Peregrine Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/42...ioblastoma
MACK: 10.43 (unch), CLDX: 25.33 (-0.21), ABBV: 70.52 (-0.04), CTIC: 1.92 (+0.01), BMY: 68.24 (-1.13), EXEL: 5.88 (-0.43)
Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 22, 9:52AM CDT
Amgen's (AMGN) potential blockbuster, Repatha, is the first PCSK9 inhibitor to gain approval in the world for the treatment of high cholesterol.
BIIB: 385.05 (-6.69), ALXN: 207.84 (+1.68), AMGN: 164.10 (-0.15), ABBV: 70.52 (-0.04), REGN: 556.61 (+0.08), FPRX: 24.47 (-0.58), EXEL: 5.88 (-0.43)
Exelixis (EXEL) Stock Declines on Secondary Public Offering
at The Street - Wed Jul 22, 8:54AM CDT
Exelixis (EXEL) shares are falling after the company announced the public offering of 20 million shares, just days after the stock spiked 50% on positive trial data.
EXEL: 5.88 (-0.43)
Biotechnology Sector Stocks Technical Coverage -- Amgen, Exelixis, XOMA Corp., Theravance, and NewLink Genetics
PR Newswire - Wed Jul 22, 8:22AM CDT
Equity Research Institute has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Theravance Inc. (NASDAQ: THRX), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research report on Amgen can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AMGN On Tuesday, July 21, 2015, the NASDAQ Composite ended at 5,208.12, down 0.21%, the Dow Jones Industrial Average declined 1.00%, to finish the day at 17,919.29, and the S&P 500 closed at 2,119.21, down 0.43%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
NLNK: 53.32 (-1.69), AMGN: 164.10 (-0.15), THRX: 15.62 (-0.25), XOMA: 1.04 (+0.04), EXEL: 5.88 (-0.43)
Exelixis proposes public offering of 20m common stock
M2 - Wed Jul 22, 4:33AM CDT
Biopharmaceutical company Exelixis (Nasdaq:EXEL) said on Tuesday that it intends to issue 20,000,000 shares of its common stock in an underwritten public offering.
EXEL: 5.88 (-0.43)
Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 5:40PM CDT
Exelixis' (EXEL) Cometriq scores in a late-stage study (METEOR) in patients with metastatic renal cell carcinoma.
EBIO: 2.91 (+0.01), AMAG: 71.31 (-1.23), NVS: 103.05 (+1.75), EXEL: 5.88 (-0.43)
Chesapeake Energy and IBM are big market movers
AP - Tue Jul 21, 3:24PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
HAS: 79.28 (-0.57), HOG: 58.25 (-0.36), CNX: 17.84 (+0.45), LMT: 202.83 (+0.04), EBAY: 28.43 (-0.02), LII: 117.39 (-0.11), CF: 62.32 (-0.20), CHK: 8.71 (-0.34), HAL: 42.33 (+0.79), CZR: 5.14 (+0.38), VZ: 46.35 (-0.10), EXEL: 5.88 (-0.43)
Exelixis Launches Proposed Public Offering of Common Stock
Business Wire - Tue Jul 21, 3:01PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today announced that it plans to offer, subject to market and other conditions, 20,000,000 shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock in connection with the offering. All of the shares of common stock in the offering will be sold by Exelixis.
EXEL: 5.88 (-0.43)
Ewing Sarcoma Pipeline Report 2015 - 15 Companies & 23 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z9h72l/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - Amgen Inc. - Cebiotex, S.L. - EntreChem, S.L. - Exelixis, Inc. - Gradalis Inc. - Kolltan Pharmaceuticals, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Oncomatrix, S.L. - Recombio S.L - Shionogi & Co., Ltd. - Sigma-Tau S.p.A. - Tesaro, Inc. Drug Profiles - 3BP-227 - cabozantinib s-malate - cancer vaccine - CEB-01 - celyvir - dactinomycin next generation - Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - EC-8042 - EC-8105 - everolimus - ganitumab - irinotecan sucrosofate liposomal - KIT-SG3227 - Monoclonal Antibody Conjugated for Ewing Sarcoma - Monoclonal Antibody to Inhibit GD2 for Oncology - MTX2-NIG - niraparib - pazopanib hydrochloride - pembrolizumab - racotumomab - S-588410 - SP-2509 - SST-0001 For more information visit http://www.researchandmarkets.com/research/z9...ng_sarcoma
MACK: 10.43 (unch), TSRO: 62.20 (-1.76), MRK: 58.07 (-0.06), AMGN: 164.10 (-0.15), NVS: 103.05 (+1.75), EXEL: 5.88 (-0.43)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 25.33 (-0.21), NBS: 2.25 (-0.09), CLSN: 2.50 (+0.09), JNJ: 100.20 (+0.02), ABBV: 70.52 (-0.04), EXEL: 5.88 (-0.43), ONCY: 0.61 (-0.03), CERU: 4.24 (+0.04), PFE: 34.78 (-0.10), IMGN: 18.15 (-0.77), AMGN: 164.10 (-0.15), LLY: 86.76 (+0.38), CLVS: 85.96 (-0.06), AZN: 66.55 (-0.67), MRK: 58.07 (-0.06), NVS: 103.05 (+1.75)
Progression Survival Benefit - BrokerBank Securities
PR Newswire - Tue Jul 21, 8:00AM CDT
Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company that develops and markets treatments for cancer. The company is in its development stage with one approved treatment. The two most advanced assets of the company are Cabozantinib, and Cobimetinib. Exelixis has five Phase III trials for various cancer treatments using Cabozantinib and Cobimetinib. On top of those, the company has numerous strategic partnerships with other drug companies, and multiple treatments in Phase II trials. Exelixis has a huge pipeline of potential uses for its treatments.
EXEL: 5.88 (-0.43)
Potential Kidney Cancer Drugs Could Revolutionize Treatment
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 21, 7:05AM CDT
Source: Bristol-Myers Squibb. If treated early enough, kidney cancer patients have a five-year survival rate that is better than many other cancers. Unfortunately, though, treatment options are more limited, and survival rates less optimistic, for...
BMY: 68.24 (-1.13), EXEL: 5.88 (-0.43)
Soft Tissue Sarcoma Therapeutics Pipeline Report 2015 - Review of 46 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vws7wm/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Altor BioScience Corporation - Amgen Inc. - Bayer AG - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - CASI Pharmaceuticals Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - Gem Pharmaceuticals, LLC - Immune Design Corp. - Karyopharm Therapeutics, Inc. - Loxo Oncology, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - MolMed S.p.A. - Morphotek, Inc. - Nanobiotix - Neotropix, Inc. - Novartis AG - Oncos Therapeutics Ltd. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/vw...oft_tissue
LOXO: 17.51 (-0.14), CLRB: 3.31 (-0.08), IMDZ: 25.82 (-1.17), PFE: 34.78 (-0.10), AMGN: 164.10 (-0.15), LLY: 86.76 (+0.38), EPZM: 22.15 (+0.05), CASI: 1.64 (-0.07), MACK: 10.43 (unch), BLCM: 18.79 (-0.32), MRK: 58.07 (-0.06), CYTR: 2.80 (-0.03), MRTX: 29.91 (-1.27), NVS: 103.05 (+1.75), KPTI: 22.95 (-0.26), EXEL: 5.88 (-0.43), CELGZ: 2.20 (-0.09)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Pipeline Review 2015 - Analysis of 35 Companies & 43 Drug Profiles
M2 - Tue Jul 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dp6kl/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca PLC - Bayer AG - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Komipharm International Co., Ltd. - Mebiopharm Co., Ltd. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - NuCana BioMed Limited - OncoTherapy Science, Inc. - Panacea Pharmaceuticals, Inc. - PCI Biotech AS - Pfizer Inc. - Provecs Medical GmbH - Sanofi - Senhwa Biosciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - AG-120 - ARN-5032 - ARQ-087 - BBI-503 - BGJ-398 - binimetinib - cabozantinib s-malate - CAP-7.1 - CC-90007 - CPI-613 - dasatinib - DKN-01 - elpamotide - evofosfamide - gemcitabine hydrochloride - Im-01 - KML-001 - MBPY-005 - melphalan - merestinib - MK-2206 - NUC-1031 - OCVC-01 - paclitaxel albumin bound - PAN-622 - pembrolizumab - ponatinib hydrochloride - porfimer sodium For more information visit http://www.researchandmarkets.com/research/6d...uct_cancer
PFE: 34.78 (-0.10), ARQL: 1.81 (-0.01), SPPI: 7.13 (-0.17), LLY: 86.76 (+0.38), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), MACK: 10.43 (unch), MRK: 58.07 (-0.06), AZN: 66.55 (-0.67), AGIO: 118.42 (+1.04), DCTH: 0.49 (-0.01), NVS: 103.05 (+1.75), ARRY: 6.59 (-0.06), CELGZ: 2.20 (-0.09), CXRX: 78.92 (+0.27), EXEL: 5.88 (-0.43)
Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 148.05 (+4.05), ARQL: 1.81 (-0.01), GALE: 1.67 (-0.03), EXEL: 5.88 (-0.43), XLRN: 31.50 (-0.68), INCY: 113.21 (-1.21), IMGN: 18.15 (-0.77), GSK: 42.00 (-0.30), ONTY: 3.60 (-0.03), AZN: 66.55 (-0.67), MRK: 58.07 (-0.06), AVEO: 1.61 (+0.01), PBYI: 98.75 (-1.25), KPTI: 22.95 (-0.26), NVS: 103.05 (+1.75)
Bristol-Myers: kidney drug win
at Investor's Business Daily - Mon Jul 20, 5:41PM CDT
The big pharma said that its Opdivo scored another win Mon. as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. The trial compared Opdivo with everolimus, better known as Novartis' (NVS) Afinitor, in...
BMY: 68.24 (-1.13), EXEL: 5.88 (-0.43), NVS: 103.05 (+1.75)
Market Wrap: A Tech-Led Tick Higher
at The Street - Mon Jul 20, 3:45PM CDT
But energy and materials names, crude oil and gold all dropped.
HOG: 58.25 (-0.36), IBM: 161.73 (+1.38), UTX: 101.14 (-0.41), SUNE: 26.30 (-1.40), KKR: 24.27 (+0.18), VSLR: 15.79 (-0.05), VZ: 46.35 (-0.10), BHI: 59.26 (+0.98), EXEL: 5.88 (-0.43)
Exelixis' Meteroric Rise From the Ashes
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 20, 1:33PM CDT
Score one for tenacity. Exelixis is up almost 50% today after releasing positive results from its phase 3 trial, dubbed Meteor, testing its drug Cometriq in patients with kidney cancer. It's been a long road to get here. Like many...
EXEL: 5.88 (-0.43)
